# Healthstream Inc: financial statements, quarterly

HSTM · Nasdaq · CIK 1095565 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hstm.md) · [Financials](/companies/hstm/financials.md) · [Filings](/companies/hstm/filings.md) · [Insiders](/companies/hstm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hstm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [70.3](/filings/0001437749-24-032036.md) | [70.6 d](/filings/0001437749-26-005916.md) | [72.8](/filings/0001437749-25-015812.md) | [71.6](/filings/0001437749-25-025468.md) | [73.1](/filings/0001437749-25-033632.md) | [74.2 d](/filings/0001437749-26-005916.md) | [73.5](/filings/0001437749-26-015213.md) | [74.4](/filings/0001437749-26-026301.md) | [76.5](/filings/0001437749-25-033632.md) | [79.7 d](/filings/0001437749-26-005916.md) | [81.2](/filings/0001437749-26-015213.md) | [83.7](/filings/0001437749-26-026301.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [10.9](/filings/0001437749-24-032036.md) | [11.9 d](/filings/0001437749-26-005916.md) | [12.0](/filings/0001437749-25-015812.md) | [12.1](/filings/0001437749-25-025468.md) | [12.1](/filings/0001437749-25-033632.md) | [12.7 d](/filings/0001437749-26-005916.md) | [12.0](/filings/0001437749-26-015213.md) | [12.1](/filings/0001437749-26-026301.md) | [12.1](/filings/0001437749-25-033632.md) | [14.8 d](/filings/0001437749-26-005916.md) | [13.6](/filings/0001437749-26-015213.md) | [13.6](/filings/0001437749-26-026301.md) |
| Operating income | $m | [4.9](/filings/0001437749-24-032036.md) | [4.3 d](/filings/0001437749-26-005916.md) | [5.7](/filings/0001437749-25-015812.md) | [4.4](/filings/0001437749-25-025468.md) | [6.5](/filings/0001437749-25-033632.md) | [4.7 d](/filings/0001437749-26-005916.md) | [4.4](/filings/0001437749-26-015213.md) | [5.9](/filings/0001437749-26-026301.md) | [7.6](/filings/0001437749-25-033632.md) | [2.4 d](/filings/0001437749-26-005916.md) | [7.5](/filings/0001437749-26-015213.md) | [8.3](/filings/0001437749-26-026301.md) |
| Income tax | $m | [1.6](/filings/0001437749-24-032036.md) | [0.8 d](/filings/0001437749-26-005916.md) | [1.3](/filings/0001437749-25-015812.md) | [1.1](/filings/0001437749-25-025468.md) | [1.8](/filings/0001437749-25-033632.md) | [0.6 d](/filings/0001437749-26-005916.md) | [0.9](/filings/0001437749-26-015213.md) | [1.5](/filings/0001437749-26-026301.md) | [2.2](/filings/0001437749-25-033632.md) | [0.3 d](/filings/0001437749-26-005916.md) | [1.9](/filings/0001437749-26-015213.md) | [2.0](/filings/0001437749-26-026301.md) |
| Net income | $m | [3.9](/filings/0001437749-24-032036.md) | [4.6 d](/filings/0001437749-26-005916.md) | [5.2](/filings/0001437749-25-033632.md) | [4.2](/filings/0001437749-25-033632.md) | [5.7](/filings/0001437749-25-033632.md) | [4.9 d](/filings/0001437749-26-005916.md) | [4.3](/filings/0001437749-26-026301.md) | [5.4](/filings/0001437749-26-026301.md) | [6.1](/filings/0001437749-25-033632.md) | [2.5 d](/filings/0001437749-26-005916.md) | [5.9](/filings/0001437749-26-026301.md) | [6.7](/filings/0001437749-26-026301.md) |
| Diluted EPS | $ per share | [0.13](/filings/0001437749-24-032036.md) | not reported | [0.17](/filings/0001437749-25-015812.md) | [0.14](/filings/0001437749-25-025468.md) | [0.19](/filings/0001437749-25-033632.md) | not reported | [0.14](/filings/0001437749-26-015213.md) | [0.18](/filings/0001437749-26-026301.md) | [0.20](/filings/0001437749-25-033632.md) | not reported | [0.20](/filings/0001437749-26-015213.md) | [0.23](/filings/0001437749-26-026301.md) |
| Basic EPS | $ per share | [0.13](/filings/0001437749-24-032036.md) | not reported | [0.17](/filings/0001437749-25-015812.md) | [0.14](/filings/0001437749-25-025468.md) | [0.19](/filings/0001437749-25-033632.md) | not reported | [0.14](/filings/0001437749-26-015213.md) | [0.18](/filings/0001437749-26-026301.md) | [0.20](/filings/0001437749-25-033632.md) | not reported | [0.20](/filings/0001437749-26-015213.md) | [0.23](/filings/0001437749-26-026301.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [44.1](/filings/0001437749-23-029097.md) | [40.3](/filings/0001437749-25-005705.md) | [52.4](/filings/0001437749-24-013221.md) | [46.1](/filings/0001437749-24-023484.md) | [57.5](/filings/0001437749-24-032036.md) | [59.5](/filings/0001437749-26-005916.md) | [77.3](/filings/0001437749-25-015812.md) | [52.1](/filings/0001437749-25-025468.md) | [53.5](/filings/0001437749-25-033632.md) | [36.2](/filings/0001437749-26-026301.md) | [48.7](/filings/0001437749-26-015213.md) | [46.2](/filings/0001437749-26-026301.md) |
| Current assets | $m | [127](/filings/0001437749-23-029097.md) | [130](/filings/0001437749-25-005705.md) | [147](/filings/0001437749-24-013221.md) | [139](/filings/0001437749-24-023484.md) | [146](/filings/0001437749-24-032036.md) | [153](/filings/0001437749-26-005916.md) | [170](/filings/0001437749-25-015812.md) | [144](/filings/0001437749-25-025468.md) | [148](/filings/0001437749-25-033632.md) | [120](/filings/0001437749-26-026301.md) | [133](/filings/0001437749-26-015213.md) | [130](/filings/0001437749-26-026301.md) |
| Total assets | $m | [498](/filings/0001437749-23-029097.md) | [500](/filings/0001437749-25-005705.md) | [512](/filings/0001437749-24-013221.md) | [500](/filings/0001437749-24-023484.md) | [503](/filings/0001437749-24-032036.md) | [511](/filings/0001437749-26-005916.md) | [524](/filings/0001437749-25-015812.md) | [500](/filings/0001437749-25-025468.md) | [500](/filings/0001437749-25-033632.md) | [520](/filings/0001437749-26-026301.md) | [527](/filings/0001437749-26-015213.md) | [522](/filings/0001437749-26-026301.md) |
| Current liabilities | $m | [115](/filings/0001437749-23-029097.md) | [118](/filings/0001437749-25-005705.md) | [126](/filings/0001437749-24-013221.md) | [112](/filings/0001437749-24-023484.md) | [111](/filings/0001437749-24-032036.md) | [116](/filings/0001437749-26-005916.md) | [126](/filings/0001437749-25-015812.md) | [115](/filings/0001437749-25-025468.md) | [112](/filings/0001437749-25-033632.md) | [124](/filings/0001437749-26-026301.md) | [137](/filings/0001437749-26-015213.md) | [123](/filings/0001437749-26-026301.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [342](/filings/0001437749-24-032036.md) | [341](/filings/0001437749-26-005916.md) | [345](/filings/0001437749-25-033632.md) | [349](/filings/0001437749-25-033632.md) | [355](/filings/0001437749-25-033632.md) | [359](/filings/0001437749-26-026301.md) | [363](/filings/0001437749-26-026301.md) | [351](/filings/0001437749-26-026301.md) | [349](/filings/0001437749-25-033632.md) | [354](/filings/0001437749-26-026301.md) | [352](/filings/0001437749-26-026301.md) | [357](/filings/0001437749-26-026301.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [24.7 d](/filings/0001437749-24-032036.md) | [13.8 d](/filings/0001437749-26-005916.md) | [20.9](/filings/0001437749-25-015812.md) | [6.5 d](/filings/0001437749-25-025468.md) | [19.1 d](/filings/0001437749-25-033632.md) | [11.2 d](/filings/0001437749-26-005916.md) | [27.1](/filings/0001437749-26-015213.md) | [5.0 d](/filings/0001437749-26-026301.md) | [18.0 d](/filings/0001437749-25-033632.md) | [13.2 d](/filings/0001437749-26-005916.md) | [27.1](/filings/0001437749-26-015213.md) | [13.4 d](/filings/0001437749-26-026301.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001437749-24-032036.md) | [0.3 d](/filings/0001437749-26-005916.md) | [0.7](/filings/0001437749-25-015812.md) | [0.2 d](/filings/0001437749-25-025468.md) | [0.3 d](/filings/0001437749-25-033632.md) | [0.2 d](/filings/0001437749-26-005916.md) | [1.1](/filings/0001437749-26-015213.md) | [2.3 d](/filings/0001437749-26-026301.md) | [0.1 d](/filings/0001437749-25-033632.md) | [0.2 d](/filings/0001437749-26-005916.md) | [0.7](/filings/0001437749-26-015213.md) | [0.9 d](/filings/0001437749-26-026301.md) |
| Dividends paid | $m | [0.8 d](/filings/0001437749-24-032036.md) | [0.8 d](/filings/0001437749-26-005916.md) | [0.8](/filings/0001437749-25-015812.md) | [0.9 d](/filings/0001437749-25-025468.md) | [0.9 d](/filings/0001437749-25-033632.md) | [0.9 d](/filings/0001437749-26-005916.md) | [0.9](/filings/0001437749-26-015213.md) | [0.9 d](/filings/0001437749-26-026301.md) | [0.9 d](/filings/0001437749-25-033632.md) | [0.9 d](/filings/0001437749-26-005916.md) | [1.0](/filings/0001437749-26-015213.md) | [1.0 d](/filings/0001437749-26-026301.md) |
| Share repurchases | $m | [1.6 d](/filings/0001437749-24-032036.md) | [7.3 d](/filings/0001437749-26-005916.md) | not reported | not reported | [0.0 d](/filings/0001437749-25-033632.md) | [0.0 d](/filings/0001437749-26-005916.md) | [0.0](/filings/0001437749-26-015213.md) | [18.1 d](/filings/0001437749-26-026301.md) | [6.9 d](/filings/0001437749-25-033632.md) | [5.0 d](/filings/0001437749-26-005916.md) | [6.7](/filings/0001437749-26-015213.md) | [2.6 d](/filings/0001437749-26-026301.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.7](/filings/0001437749-23-029097.md) | [30.7](/filings/0001437749-24-013221.md) | [30.8](/filings/0001437749-24-023484.md) | [30.8](/filings/0001437749-24-032036.md) | [30.4](/filings/0001437749-25-015812.md) | [30.5](/filings/0001437749-25-025468.md) | [30.6](/filings/0001437749-25-033632.md) | [30.6](/filings/0001437749-26-015213.md) | [30.5](/filings/0001437749-26-026301.md) | [29.8](/filings/0001437749-25-033632.md) | [29.4](/filings/0001437749-26-015213.md) | [29.3](/filings/0001437749-26-026301.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,239,955 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001437749-26-026301.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.